Related Experiment Video
Updated: Jun 7, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Characterization of a new solvate of risedronate
Jürgen Brüning1, Anna Christine Petereit, Edith Alig
1Institute of Inorganic and Analytical Chemistry, Goethe-University, Max-von-Laue-Str. 7, 60438 Frankfurt am Main, Germany.
Abstract:
Three new forms of the osteoporosis drug sodium risedronate, sodium [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonate, were identified and designated as the J, K, and M phases. Form J is an acetic acid disolvate with the chemical composition Na(+) [C(7) H(10) NO(7) P(2)](-) · 2CH(3) COOH, as determined by single-crystal structure analysis. This novel solvate is easily formed by the recrystallization of sodium risedronate from acetic acid. Dissolution of the new disolvate was characterized in distilled water, a compendial buffer, simulated gastric fluid sine pepsin (pH 1.2), and a biorelevant buffer system FaSSIF-V2 (pH 6.8). It was demonstrated that solubility of the disolvate in physiological buffers differed significantly from that of the original molecule, with delayed dissolution under simulated esophageal and gastric conditions, but rapid and complete dissolution under simulated intestinal conditions. These studies suggest that through the generation of novel solvates, the biopharmaceutical properties of poorly soluble drug candidates can be improved.
Related Concept Videos
Ionic Strength: Effects on Chemical Equilibria
In this solution, the primary cation—the calcium...
Phase I Reactions: Reductive Reactions
Osteoclasts in Bone Remodeling
Solubility Equilibria: Overview
Solubility is important in biological and environmental processes. A notable...
Factors Affecting Solubility
Formation of Complex Ions
